The growing demand for protein-based drugs is a key factor driving the global peptide therapeutics market, says Fortune Business Insights in a report, titled “Peptide Therapeutics Market Size, Share & Industry Analysis, By Product Type (Generic, Innovative (Patented)), By Route of Administration (Parenteral, Oral, Nasal), By Application (Central Nervous System Disorders, Respiratory Disorders, Metabolic Disorder, Allergy/Immunological), By End-user (Pharmaceutical & Biotechnology Industries, Academic & Research Institutes, Contract Research Organization) and Regional Forecast, 2019-2026.” The increasing product launches by key players is expected to aid the growth of the global peptide therapeutics market.
Browse Complete Report:
List Of The Major Companies That Are Present In The Global Peptide Therapeutics Market Are:
- Bachem Holding AG
- Eli Lilly, and Company
- Pfizer Inc.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd
- Lonza Inc.
- Sanofi S.A.
- Bristol-Myers Squibb (BMS)
According to the report, the rising R&D investments in drug development by key players is expected to aid growth of the global peptide therapeutics market during the forecast period. In addition, several advantages offered by Peptide therapeutics such as increased potency & selectivity is further expected to fuel demand for peptide therapeutics, which, in, turn will boost peptide therapeutics market revenue.
The report contains an exclusive set of data to benefit and enable companies to work on their strategies for the overall development. The report provides information regarding market drivers, new advancement and recent trends in the global peptide therapeutics market.
Get Sample PDF:
Increasing R&D Activities Will Boost Growth In North America
Geographically, the global peptide therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Asia and Africa. North America is expected to dominate the global peptide therapeutics market owing to the presence of many pharmaceutical companies and rising R&D activities in the proteomics & genomics sector, and investments by key players in developing innovative peptide drug molecules.
In Europe, increasing awareness about the applications of peptide for the treatment of various chronic diseases is likely to boost the peptide therapeutics market growth during the forecast period. In the Asia Pacific is peptide therapeutics market is predicted to grow at a significant rate owing to the growing patient population and the presence of many key players involved in life science research.In addition, the rising patient pool is expected to further create growth opportunities
Increasing Prevalence Of Chronic Diseases Will Propel Growth
The increasing prevalence of chronic disease and rising geriatric patient population is expected to encourage the growth of the global peptide therapeutics market. The rapidly growing technological advancement and rising improvement in the automation process & purity is predicted to propel the growth of the peptide therapeutics market.
The rising awareness about the growing application of peptides in the treatment of various diseases is likely to boost the peptide therapeutics market during the forecast period. Further, the product launches and collaborations between key players is expected to enable growth of the peptide therapeutics market. For instance, PeptiDream Inc. and Novartis AG signed new Peptide Drug Conjugate “PDC” collaboration agreement to initiate macrocyclic peptide discovery, which will be used to address therapeutic and diagnostic application.
Moreover, Alexion Pharmaceuticals, Inc. collaborated with Zealand Pharma A/S with the goal to discover and develop peptide therapies subcutaneously delivered peptide therapies directed to up to four complement pathway targets.
The collaboration is predicted to create new growth opportunities for the global peptide therapeutics market. In addition, the increasing mergers by key companies for the development of Computationally-designed protein therapeutics will stimulate growth. For instance, Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. entered into mergers agreement with an aim to develop and commercialize Computationally-designed protein therapeutics to address significant unmet medical needs in immuno-oncology, inflammation, and autoimmunity.
Speak to Analyst:
Secondary Research is conducted to derive the following information:
- Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies.
- Details in relation to the parent market/related market, value and supply chain analysis, distribution channels, trade analysis, and recent technological developments.
- Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities.
- Market & technological trends and new product developments
View Related Reports: